For people with chronic kidney disease (CKD) undergoing dialysis using an arteriovenous fistula or graft, what are the effects of omega-3 fatty acids?

2019 ◽  
Author(s):  
Jane Burch ◽  
Elisabeth Hodson
Keyword(s):  
Chronic Kidney Disease ◽  
Fatty Acids ◽  
Kidney Disease ◽  
Arteriovenous Fistula ◽  
Omega 3 Fatty Acids ◽  
Omega 3

scholarly journals Omega‐3 Fatty Acids Mitigate Inflammation in Felines with Chronic Kidney Disease

2012 ◽  
Vol 26 (S1) ◽  
Author(s):  
Mary A Harris ◽  
Katharine Lunn ◽  
Jessica Quimby ◽  
Susan Kim ◽  
Christopher Mulligan
Keyword(s):  
Chronic Kidney Disease ◽  
Fatty Acids ◽  
Kidney Disease ◽  
Omega 3 Fatty Acids ◽  
Omega 3

scholarly journals Therapeutic Effects of Omega-3 Fatty Acids on Chronic Kidney Disease-Associated Pruritus: a Literature Review

2016 ◽  
Vol 6 (4) ◽  
pp. 509-514 ◽  
Author(s):  
Yunes Panahi ◽  
Simin Dashti-Khavidaki ◽  
Farahnoosh Farnood ◽  
Hamid Noshad ◽  
Mahsa Lotfi ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Fatty Acids ◽  
Kidney Disease ◽  
Literature Review ◽  
Therapeutic Effects ◽  
Omega 3 Fatty Acids ◽  
Omega 3

scholarly journals Oral supplementation with omega-3 fatty acids and inflammation markers in patients with chronic kidney disease in hemodialysis

2020 ◽  
Vol 45 (8) ◽  
pp. 805-811
Author(s):  
José A. Valle Flores ◽  
Juan E. Fariño Cortéz ◽  
Gabriel A. Mayner Tresol ◽  
Juan Perozo Romero ◽  
Miquel Blasco Carlos ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Fatty Acids ◽  
Kidney Disease ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Inflammation Markers ◽  
Oral Supplementation ◽  
Reactive Protein ◽  
Group A ◽  
Group B

Chronic kidney disease (CKD) is an increasingly common public health problem that increases the risk of death because of cardiovascular complications by 2–3 times compared with the general population. This research concerns a prospective, randomized, double-blind study in patients with CKD undergoing hemodialysis. The participants were assigned to 1 of 2 groups: the study group (group A; 46 patients) received 4 capsules (2.4 g) of omega-3 fatty acids daily during the 12-week intervention, while patients in the control group (group B; 47 patients) received 4 capsules of paraffin oil. The patients’ general characteristics, nutritional indicators, renal disease markers and inflammatory markers (C-reactive protein, interleukin (IL)-6, IL-10, and tumour necrosis factor alpha (TNF-α)) were evaluated. No differences were found between the general characteristics of the patients (P < 0.05), and no differences were shown in the nutritional indicators and markers of kidney disease (P < 0.05). Patients in group A showed significant decreases in levels of C-reactive protein, IL-6, TNF-α, and the IL-10/IL-6 ratio after 12 weeks of supplementation (P < 0.05). Patients in group B did not show any significant changes in concentrations of inflammatory markers during the intervention (P < 0.05). In conclusion, oral supplementation with omega-3 fatty acids produces a significant decrease in the concentrations of inflammation markers in patients with chronic kidney disease on hemodialysis. Novelty Oral supplementation with omega-3 fatty acids produced significant decreases in the concentrations of inflammation markers. This supplementation could be given to patients with uremic syndrome and coronary heart disease to reduce cardiovascular risk.

Plasma and urinary F2-isoprostane markers of oxidative stress are increased in cats with early (stage 1) chronic kidney disease

2020 ◽  
pp. 1098612X2096935
Author(s):  
Martin Granick ◽  
Allison S Leuin ◽  
Lauren A Trepanier
Keyword(s):  
Oxidative Stress ◽  
Chronic Kidney Disease ◽  
Fatty Acids ◽  
Kidney Disease ◽  
Late Stage ◽  
Early Stage ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Renal Diet ◽  
Stage 1

Objectives Oxidative stress contributes to chronic kidney disease (CKD) progression in humans and rodent models; F2-isoprostanes (F2-IsoPs) are established biomarkers of oxidative stress. Our primary aim was to evaluate plasma F2-IsoPs in cats with International Renal Interest Society stage 1 and 2 CKD, compared with healthy cats, and to determine whether plasma and urinary F2-IsoPs are equivalent biomarkers. The secondary aim was to assess whether consumption of a renal diet enriched in omega-3 fatty acids led to improvements in plasma and urinary F2-IsoPs. Methods Plasma and urinary F2-IsoPs were measured in 24 cats with stage 1 or 2 CKD, and 12 unaffected controls aged ⩾6 years. Twelve CKD cats were re-evaluated after feeding a commercial renal diet for at least 4 weeks. Results Median plasma F2-IsoPs were significantly higher in stage 1 CKD (96.2 pg/ml), early stage 2 CKD (83.2 pg/ml) and late stage 2 CKD (80.8 pg/ml) compared with healthy cats (22.8 pg/ml; P = 0.03−0.002). Median urinary F2-IsoPs were significantly higher in cats with stage 1 CKD (231.2 pg/mg) compared with healthy cats (152.5 pg/mg) or cats with late stage 2 CKD (124.8 pg/mg; P = 0.01). Plasma F2-IsoPs remained increased, while urinary F2-IsoPs fell with transition from stage 1 to stage 2 CKD. Feeding a commercial renal diet led to significant decreases in plasma F2-IsoPs in the small group of cats with stage 1 CKD (25−75% decrease) compared with cats with stage 2 CKD (20% decrease to 53% increase; P = 0.01). Conclusions and relevance Oxidative stress is prominent in cats with stage 1 CKD. Plasma and urinary F2-IsoPs are not interchangeable biomarkers in cats with stage 2 CKD. Placebo-controlled studies are indicated to evaluate dietary or pharmacologic doses of omega-3 fatty acids on redox stress and progression of renal dysfunction in cats with stage 1 CKD.

scholarly journals Impact of Blood or Erythrocyte Membrane Fatty Acids for Disease Risk Prediction: Focusing on Cardiovascular Disease and Chronic Kidney Disease

Nutrients ◽  
2018 ◽  
Vol 10 (10) ◽  
pp. 1454 ◽  
Author(s):  
Oh Kim ◽  
Su Lee ◽  
Won An
Keyword(s):  
Cardiovascular Disease ◽  
Chronic Kidney Disease ◽  
Fatty Acids ◽  
Kidney Disease ◽  
Erythrocyte Membrane ◽  
Risk Prediction ◽  
Disease Risk ◽  
Omega 3 ◽  
Cvd Risk ◽  
Coronary Syndrome

Fatty acids (FAs) are essential nutrients and main constituents of cell membranes that are involved in the signaling pathway and associated with health conditions. We investigated if blood or erythrocyte membrane FAs can predict the risk of cardiovascular disease (CVD), chronic kidney disease (CKD), and related complications. Omega-3 (n-3) FAs are important predictors for metabolic syndrome, diabetes, CVD, and CKD risks, and the n-3 index is also a good biomarker for sudden cardiac death in coronary artery disease. Linoleic acid, which is one of the major n-6 FAs reflecting recent dietary FA intake, may predict CVD risk and mortality in the general population and patients with CKD. Monounsaturated FAs (MUFAs) are also related to diabetes or diabetic nephropathy. Oleic acid, a major MUFA, is an emerging marker that is related to acute coronary syndrome, low glomerular filtration rate, and vascular calcification in patients with CKD, and can be modified by n-3 FA supplementation. Saturated FAs, trans-FAs, and FA desaturation/elongation are associated with CVD risk; however, few studies have been conducted on patients with CKD. In summary, blood or erythrocyte membrane FA measurements are important for CVD and CKD risk prediction and management. Further studies are needed to elucidate the FAs for their risk predictions.

Sign in / Sign up

Export Citation Format

Share Document